Digital Turbine (APPS) Tops Q4 EPS by 2c, Revenues Miss

Digital Turbine (NASDAQ: APPS) reported Q4 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $21 million versus the consensus estimate of $26.53 million.

Fourth Quarter Fiscal 2018 Financial Results

• Total revenue for the fiscal fourth quarter of 2018 was $21.0 million, representing an increase of 81% year-over-year. Revenue growth was attributable to year-over-year growth with large pre-existing carrier partners as well as incremental contributions from new carrier and OEM partners more recently added to the Ignite platform.
• GAAP gross margin increased to 33% for the fourth quarter of fiscal 2018, as compared to 28% GAAP gross margin in the fiscal fourth quarter of 2017. Non-GAAP adjusted gross margin4 was 36% for the fiscal fourth quarter of 2018, as compared to 38% for the fiscal fourth quarter of 2017. The reconciliation between GAAP and Non-GAAP financial results for all referenced periods is provided in a table immediately following the Unaudited Consolidated Statements of Operations and Comprehensive Loss below.
• Net loss for the fourth quarter of fiscal 2018 was $4.2 million, or ($0.06) per share, as compared to the net loss for the fiscal fourth quarter of 2017 of $5.8 million, or ($0.09) per share. Non-GAAP adjusted net loss1 for the fourth quarter of fiscal 2018 was $0.6 million, or ($0.01) per share, as compared to a Non-GAAP adjusted net loss of of $1.5 million, or ($0.02) per share, during the fiscal fourth quarter of 2017.

Business Outlook

• Based on information available as of June 12, 2018, the Company expects first quarter of fiscal 2019 revenue of approximately $23 million and positive non-GAAP adjusted EBITDA2.

For earnings history and earnings-related data on Digital Turbine (APPS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AXT appoints Tracy Liu to its board of directors
• Pfizer lung cancer drug misses survival goal in Phase 3 trial